Pharma Capsules - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharma Capsules
Brief pharmaceutical news items for July 2009.

Pharmaceutical Technology
Volume 33, Issue 7, pp. 90

Q&A with Gerry Migliaccio, vice-president of quality; environment, health, and safety; and agility at Pfizer

PharmTech:



What is the biggest industry challenge you're now facing?

Migliaccio:

The pharmaceutical industry is facing the same challenges as many other industries as a result of the economic situation, plus a few unique challenges such as successfully bringing new medicines to market and changing payors' expectations. From the pharmaceutical manufacturing perspective, I think one of our biggest challenges is securing our supply chains as they become truly global. The challenge includes the prevention and detection of counterfeits, the prevention of product diversion, and the prevention of intentional (i.e., criminal) adulteration.

PharmTech:

How do you stay abreast of new developments in the industry?

Migliaccio:

I try to interact with industry colleagues and regulators as often as possible at industry association meetings, which is where you can get a true sense of new developments from the perspective of industry and the regulatory agencies. For my daily dose of current industry affairs, I review Dickinson's FDA Webview and several other online newsletters.

PharmTech:

Do you see a new industry trend emerging?

Migliaccio:

I see quite a few trends in the manufacturing arena. The trend toward outsourcing will continue. Strategies widely used in other industries such as continuous processing are taking hold in pharmaceutical manufacturing and will emerge in the coming years. As quality by design continues to be adopted and our manufacturing processes become better understood and highly capable, reliance on product testing will be reduced significantly.

Gerry Migliaccio will be a keynote speaker at Pharmaceutical Technology's Third Annual Conference to be held Aug. 11–12, 2009, in Philadelphia. For program details and to register, visit http://www.pharmtechevent.com


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here